Nuvation Bio Gains FDA Fast Track for Safusidenib

New York, New York, August 20, 2026

FDA Fast Track Supports Safusidenib Development

The FDA’s Fast Track Designation is intended to facilitate the development and expedite the review of investigational medicines designed to treat serious conditions where there is an unmet medical need. For safusidenib, the designation provides opportunities for more frequent interactions between Nuvation Bio and the FDA during the drug-development process. If applicable criteria are met, the program may also allow rolling review of a marketing application, enabling completed portions of an application to be submitted for regulatory review before the full application is completed. These mechanisms are intended to potentially shorten the development and review timeline for promising therapies. The designation was supported by clinical data generated through the safusidenib development program, including updated long-term findings from the Phase 2 J201 study, which demonstrated durable responses and a favorable reported risk-benefit profile. At a median follow-up of 38.8 months, safusidenib achieved a confirmed objective response rate of 51.9%, while median progression-free survival had not yet been reached. The reported 36-month progression-free survival rate was 79.1%, and only one previously responding patient subsequently experienced disease progression. Nuvation Bio reported that no new safety signals were identified during longer-term follow-up.

Phase 3 SIGMA Study Advances in Glioma

Safusidenib is being evaluated in multiple clinical settings involving patients with IDH1-mutant glioma, including populations with limited or no approved targeted treatment options. The pivotal Phase 3 SIGMA (G203) study is designed to compare safusidenib with placebo as maintenance therapy following standard-of-care treatment in patients with IDH1-mutant astrocytoma with high-risk features. The pivotal portion of the trial is expected to enroll approximately 300 patients, providing a substantially larger dataset for evaluating the investigational therapy. A separate exploratory, non-pivotal cohort is evaluating safusidenib in patients with grade 3 IDH1-mutant oligodendroglioma who have not previously received chemotherapy or radiotherapy. This cohort is expected to enroll approximately 40 participants, with objective response rate serving as the primary endpoint. Nuvation Bio is also advancing additional Phase 3 and Phase 2 studies in other geographic and treatment settings, including the G307 study outside the United States and the G209 study evaluating safusidenib following treatment with vorasidenib.

Targeted Therapy Addresses Unmet Brain Cancer Need

IDH1-mutant gliomas represent an important molecularly defined segment of adult brain cancer. The company states that nearly 2,500 people in the United States are diagnosed with IDH-mutant gliomas annually, with more than 95% of these tumors harboring an IDH1 mutation. Patients are frequently diagnosed in their 30s and 40s, and although IDH1-mutant gliomas can have longer survival than IDH1-wild-type disease, they remain incurable, particularly when high-risk features are present. Safusidenib is designed to selectively inhibit mutant IDH1 and is formulated to penetrate the brain, an important characteristic for therapies targeting central nervous system tumors. The FDA Fast Track designation therefore represents a significant regulatory milestone as Nuvation Bio progresses its clinical development strategy. With the Phase 3 SIGMA study actively enrolling, the company is working to determine whether the encouraging clinical activity observed in earlier studies can translate into meaningful benefits for patients with IDH1-mutant glioma. The program also highlights the continued development of precision oncology therapies targeting specific molecular drivers of cancer and the role of accelerated regulatory pathways in supporting treatments for serious diseases with substantial unmet medical needs.

Source: Nuvation Bio press relese